The objective of the study is to assess the efficacy and safety of home use of a Control-to-Range (CTR) closed-loop (CL) system.
The protocol is a 3-month parallel group multi-center randomized trial designed to compare Control-to-Range (CTR) closed-loop (CL) with sensor augmented pump therapy (SAP). Approximately 126 subjects will be entered into the randomized trial at approximately seven clinical sites in the United States, such that at least 110 subjects complete the randomized trial. A maximum of 200 subjects may be enrolled in the study in order to achieve the goal of randomizing 126 subjects. In order to have a broad range of glycemic control among the subjects, a study goal will be to have a minimum of 50 subjects with HbA1c ≥ 7.5% and 50 with HbA1c \< 7.5%.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
127
Use of CTR at home for 3 months
Use of personal pump with study CGM \& glucometer at home for 3 months
William Sansum Diabetes Center
Santa Barbara, California, United States
Stanford University
Stanford, California, United States
Barbara Davis Center, University of Colorado
Aurora, Colorado, United States
Harvard University (Joslin Diabetes Center)
Boston, Massachusetts, United States
Time Below 70 mg/dL
CGM-measured % time below 70 mg/dL - 1st co-primary outcome (superiority)
Time frame: Post randomization (final 11 weeks)
Time Above 180 mg/dL
CGM-measured % time above 180 mg/dL - 2nd co-primary outcome (noninferiority)
Time frame: Post randomization (final 11 weeks)
Time Below 54 mg/dL
Percent time CGM readings were below 54 mg/dL
Time frame: Post randomization (final 11 weeks)
Time Below 60 mg/dL
CGM-measured % time below 60 mg/dL
Time frame: Post randomization (final 11 weeks)
Time in Range 70-180 mg/dL
CGM-measured % in range 70-180 mg/dL
Time frame: Post randomization (final 11 weeks)
Time in Range 70-140 mg/dL
CGM-measured % time in range 70-140 mg/dL
Time frame: Post randomization (final 11 weeks)
Time Above 250 mg/dL
CGM-measured % time above 250 mg/dL
Time frame: Post randomization (final 11 weeks)
Time Above 300 mg/dL
CGM-measured % time above 300 mg/dL
Time frame: Post randomization (final 11 weeks)
Coefficient of Variation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mayo Clinic
Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
University of Virginia Center for Diabetes Technology
Charlottesville, Virginia, United States
CGM-measured coefficient of variation (CV)
Time frame: Post randomization (final 11 weeks)